August 14, 2023
Step into Pharma’s Age of Uncertainty, where all is in flux. From the FDA’s shifting mood and the ripple effects of the IRA to commercial upheavals, dealmaking uncertainties and emerging R&D mechanisms, we’ve identified the pivotal forces that are redefining the pharma and biotech landscape out to 2028.
Download Evaluate’s World Preview 2023: Pharma’s Age of Uncertainty report here.
Share
Understand the context. Data-driven news and analysis for the pharma, biotech and medtech sectors.
September 5, 2024
Solid proof now exists that pharmacological intervention can help shift excess body weight. Yet, many questions remain, including: What’s the potential market size? How much is the pipeline worth? Which ...
August 19, 2024
Navigating the complex landscape of rare diseases requires a specialized approach. With over 7,000 types of rare diseases affecting more than 300 million people globally, and only a fraction having ...
August 12, 2024
Going into 2024, hopes were moderately high for dealmaking and the wider financial landscape in pharma. M&A and IPOs were picking up, offering investors the exit opportunities they need. But ...
Do the pharmaceutical industry’s billion-dollar drugs have an X-factor? To better understand the blockbuster landscape and identify the key characteristics driving their success, we’ve analysed Evaluate Pharma data on nearly ...
July 9, 2024
Last year’s Age of Uncertainty has given way to more predictable realities. Obesity drugs are set to dominate the 2030 forecasts, with more potent compounds, combinations, and oral formulations likely ...
After an Age of Uncertainty, the pharmaceutical industry is now shifting into a period with more predictable trends, where big pharma continues to focus on big drugs for big diseases. ...
